MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease

Decipher (and other MolDX‑approved equivalent genomic assays) is covered for men with localized or biochemically recurrent prostate adenocarcinoma, life expectancy >=10 years, when the result will inform guideline‑based treatment decisions and the patient is a candidate for specified management scenarios (e.g., definitive therapy, ADT decisions, adjuvant/salvage radiotherapy, or systemic therapy intensification). Coverage requires FFPE prostate tissue (biopsy with >=0.5 mm linear tumor or resection specimen), no prior pelvic radiation or ADT before the specimen, and clinical monitoring per standards; other genomic tests require MolDX technical assessment demonstrating equivalent analytic and clinical validity.

"Male patients with localized (non-metastatic) or biochemically recurrent prostate adenocarcinoma and life expectancy >= 10 years are eligible for the Decipher genomic classifier when they are candi..."